If your infusion suite stocks more than one infliximab product, you already know the headache. Remicade and its biosimilars, Inflectra, Renflexis, and Avsola, treat the same conditions but they do not share a billing code. Get the code wrong and the claim either denies outright or pays at the wrong rate. Here is the plain-English breakdown of what has to line up on that claim.
A quick note before we start: HCPCS codes (the codes Medicare and most payers use to bill drugs and supplies) and payer policies change. Treat every code below as a starting point, not gospel, and confirm the current version with your billing software, your Medicare Administrative Contractor, or the payer's fee schedule before you submit.
Why Remicade and Its Biosimilars Don't Share One Code
Each infliximab product has its own J-code, which is the HCPCS code used to bill a specific injectable or infusion drug. As of this writing, the common assignments are:
- J1745 for Remicade, the original brand infliximab
- Q5103 for Inflectra
- Q5104 for Renflexis
- Q5121 for Avsola
These are not interchangeable on a claim. If your pharmacy dispensed Inflectra but the biller pulled J1745 out of habit because that's what the practice used for years, that line item does not match what was actually infused. That mismatch is exactly the kind of thing that triggers a denial or, worse, gets paid and then flagged in an audit later. We walked through the full buy and bill process, meaning the practice purchases the drug and bills the payer back for it, in our rheumatology infusion billing guide, and code selection is where a lot of that process quietly breaks down.
Put the Right NDC on the Claim
The NDC, or National Drug Code, is the number printed on the vial that identifies the exact manufacturer, product, and package size. Many payers now want the NDC on the claim line in addition to the HCPCS code, even though historically only the HCPCS code drove payment.
The units billed are still based on the HCPCS code description, not the NDC. For infliximab products, the HCPCS unit is typically defined in a set number of milligrams, so you calculate units from the dose given, not from the vial size. Your EHR or infusion charting tool should be pulling this automatically, but it is worth spot checking a few claims a month to make sure the NDC on file actually matches the product your pharmacy bought and stocked that quarter, especially if your practice switches vendors or formulary preference changes.
JZ and JW Modifiers: Say What Happened to Every Milligram
Infliximab comes in single-dose vials, meaning the vial is meant to be used once and any leftover drug cannot be saved for another patient. That leftover amount is called drug waste, and payers want to know exactly what happened to it.
Two modifiers handle this:
- JW modifier is added to a separate claim line to bill for the amount of drug that was drawn up but not administered and had to be discarded.
- JZ modifier is added when there was zero waste, meaning the entire vial was used on the patient.
Medicare made one of these two modifiers mandatory on single-dose vial claims, and many commercial payers have followed suit. Skipping the modifier entirely, rather than picking the right one, is one of the more common reasons these claims bounce back. If your infusion nurses are already documenting waste in the chart for inventory purposes, make sure that number is actually making it onto the claim, not just staying in the clinical note.
Pairing the Drug Line With the Infusion Administration Code
The drug itself is only half the claim. You also need a code for the work of actually running the infusion. For infliximab and its biosimilars, that is typically:
- 96413 for the initial infusion, up to one hour
- 96415 for each additional hour beyond the first
These codes require accurate start and stop times in the chart. If the nursing documentation says the infusion ran two hours and ten minutes but the claim only bills one unit of 96415, you are leaving money on the table. If the times are missing altogether, expect the payer to ask questions or deny the add-on time. This is the same documentation gap we cover in more depth in the rheumatology infusion billing guide, since it comes up constantly in infusion-heavy specialties.
Check Which Product the Payer Prefers Before You Buy the Drug
Here is the part that trips up even experienced billing teams: many payers have a preferred infliximab product, often the lowest-cost biosimilar, and require it as a step before they will cover the brand or a different biosimilar. This is a form of step therapy, meaning the payer wants you to try a specific product first.
If your practice buys and infuses a product the payer does not prefer without checking first, you risk a denial on the drug charge even though the administration and diagnosis were all appropriate. This is why the buy decision needs to happen after a benefits check and prior authorization confirmation, not before. If prior auth turnaround is already a bottleneck for your team, our checklist on speeding up prior authorization is worth a look, and if you are seeing a pattern of infusion drug denials specifically, our piece on why claims keep getting denied covers several causes that show up often with biologics.
A Quick Example
Say a patient is infused with Inflectra, 300 mg, with zero waste, and the infusion runs one hour and 45 minutes. As an illustration only, the claim lines would generally include: Q5103 with the correct unit count for 300 mg, the JZ modifier since nothing was discarded, 96413 for the first hour, and one unit of 96415 for the additional 45 minutes, which most payers round up to a full unit. Your actual billing will depend on your payer's specific rounding rules and current fee schedule, so confirm before submitting.
Where This Fits Into Your Bigger Picture
Biosimilar billing is a good example of why infusion and specialty drug claims need a second set of eyes, whether that is a trained biller, a billing company, or increasingly, an AI agent built specifically to check drug codes, NDCs, modifiers, and payer preference before a claim goes out the door. We talk through the tradeoffs of each option in in-house biller vs billing company vs AI if you are weighing your options there.
If you want a clearer picture of where your own infusion claims are getting stuck, whether it's code mismatches, missing modifiers, or payer preference issues, the free Billing Health Check is a straightforward way to see it laid out without committing to anything.
Frequently Asked Questions
Is Remicade billed the same way as its biosimilars?
No. Remicade uses HCPCS code J1745, while its biosimilars each have their own code, such as Q5103 for Inflectra, Q5104 for Renflexis, and Q5121 for Avsola. Billing the wrong code for the product actually infused is a common cause of denials, so always confirm the current code list before submitting.
When do I use the JZ modifier versus the JW modifier for infliximab?
Use the JW modifier when part of the single-dose vial was drawn up but not administered and had to be discarded. Use the JZ modifier when the entire vial was used on the patient with zero waste. Medicare requires one of these two modifiers on single-dose vial claims, and many commercial payers now expect it too.
Which infusion administration codes pair with infliximab drug codes?
Infliximab infusions are typically billed with 96413 for the initial hour of infusion and 96415 for each additional hour beyond that, based on documented start and stop times. These are separate claim lines from the drug code itself, and both need to reflect what actually happened during the visit.
Why does my infliximab claim get denied even when the diagnosis is correct?
A common reason is that the payer has a preferred infliximab product, often a specific biosimilar, and requires proof it was tried or approved before covering a different one. Checking the payer's product preference and prior authorization status before purchasing the drug can prevent this type of denial.